Agribiotech lobby group ISAAA reports that global GMO acreage has grown to 189.8 million hectares in 2017 -3% or 4.7 million hectares more than in 2016.

Ecteinascidia turbinata. © PharmaMar SA

Roche’s Japanese arm Chugai today returned all rights from a 2016 licence agreement on the RNA polymerase II blocker lurbinectedin to Spanish oncology specialist PharmaMar SA.

Thomas Videbaeck. Picture: Novozymes

How do novel technologies affect the world’s largest enzyme producer? At the GBS, European Biotechnology asked Thomas Videbaeck, PhD, COO and Executive VP Research, Innovation and Supply.

© NodThera Ltd.

Selvita spin-out NodThera Ltd raised £28 million (€31.8m) in a Series A financing round led by Sofinnova Partners and 5AM Ventures and co-financed by Epidarex Capital and F-Prime Capital Partners.

Dave Lemus. Image Credit: Morphosys AG

Silence Therapeutics plc, a company active in the development of RNA therapeutics, has announced the appointment of Dave Lemus to its Board as Non-Executive Director. 

EB_online_ian-mcgowan-square.jpg

Abivax, a biotechnology company working to develop a functional cure for HIV as well as treatments for inflammatory/autoimmune diseases and cancer, appoints Ian McGowan as Scientific Advisory Board Chair and Juergen Rockstroh as a New Member to the Company’s SAB. The changes have been made to support the transition from a discovery-focused biotechnology company to a biopharmaceutical development company.

Structural differences between memory T cells from the spleen, and small intestinal IELs. © Konjar et al., Sci. Immunol. 3, eaan2543 (2018)

Special immune cells that protect the lining of the gut remain in a semi-active state, ready to fend off a pathogen at any moment, thanks to the composition of their mitochondrial membrane, a new study reveals.

A representation of the EGFR protein, which plays a role in the progression of lung tumors driven by mutations in the KRAS protein. ©bbiolution GmbH

A team of Austrian, Hungarian and Canadian researchers has demonstrated that Boehringer Ingelheim’s FDA-approved ERB family kinase blocker afatinib prolonged survival in hard-to-treat K-RAS-mutated lung tumours.

Novimmune's CD47xCD19 bi-specific antibody. © Novimmune SA

Swiss Novimmune SA has exclusively sold a licence option on its lead product NI-1701 (now renamed TG-1801), a bispecific anti-CD47/anti-CD19 antibody designed to trea B-cell blood cancers, to TG Therapeutics Inc.

Michael Carus, The founder 
and Managing Director of the nova-Institute studied physics and mathematics at the University of Cologne. Carus became a lecturer at the University of Tübingen, on the topics of ecology, nuclear energy, and radioactivity. He worked as a science journalist and 
scientist at the KATALYSE Environmental Institute with a focus on energy, ecology, and renewable resources, and two years in the solar industry. In 1994, he founded the nova-Institute for Ecology and Innovation. © Nova Institute, Cologne

Plastics are magical materials, and they will be even more important in the future than they are today. But they lead to microplastics in the environment, especially noticeable as marine littering. The European Commission is now proposing, among other things, a ban on certain single-use plastic products, including plastic cotton buds, cutlery, plates, straws, drink stirrers, and sticks for balloons, which will all have to be made exclusively from more sustainable materials instead. The Commission’s legislative proposal must then be negotiated with the member states and the European Parliament. And here substantial changes should still be made because so far industry and politics continued to fail in this area.